| Dr Joseph Alder Troncale, MD | |
|
1101 Edgar St, York, PA 17403-2862 | |
| (717) 851-1500 | |
| (717) 851-1515 |
| Full Name | Dr Joseph Alder Troncale |
|---|---|
| Gender | Male |
| Speciality | Addiction Medicine |
| Experience | 45 Years |
| Location | 1101 Edgar St, York, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710066006 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083A0300X | Preventive Medicine - Addiction Medicine | MD041009E (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellspan Medical Group | 1951213115 | 1946 |
| Florida Pain Management Associates, P.a. | 3678532470 | 3 |
News Archive
Researchers in the U.S. and U.K. are conducting an ongoing investigation of the cognitive effect of fetal exposure across four commonly used antiepileptic drugs (AEDs) as part of an NIH-funded Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study. An early NEAD analysis found that fetal exposure to valproate impairs IQ at age three.
EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.
Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc., a member of the Roche Group, announced today a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20
Genetics plays a key role in determining risk for colorectal cancer, the second leading cause of cancer-related deaths in the United States.
› Verified 6 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
Researchers in the U.S. and U.K. are conducting an ongoing investigation of the cognitive effect of fetal exposure across four commonly used antiepileptic drugs (AEDs) as part of an NIH-funded Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study. An early NEAD analysis found that fetal exposure to valproate impairs IQ at age three.
EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.
Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc., a member of the Roche Group, announced today a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20
Genetics plays a key role in determining risk for colorectal cancer, the second leading cause of cancer-related deaths in the United States.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph Alder Troncale, MD 3421 Concord Rd, York, PA 17402-9001 Ph: (717) 851-1500 | Dr Joseph Alder Troncale, MD 1101 Edgar St, York, PA 17403-2862 Ph: (717) 851-1500 |
News Archive
Researchers in the U.S. and U.K. are conducting an ongoing investigation of the cognitive effect of fetal exposure across four commonly used antiepileptic drugs (AEDs) as part of an NIH-funded Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study. An early NEAD analysis found that fetal exposure to valproate impairs IQ at age three.
EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.
Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc., a member of the Roche Group, announced today a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20
Genetics plays a key role in determining risk for colorectal cancer, the second leading cause of cancer-related deaths in the United States.
› Verified 6 days ago
Timothy L Allen, D.O. Preventive Medicine Medicare: Medicare Enrolled Practice Location: 716 Loucks Rd, York, PA 17404 Phone: 615-778-4066 | |
Hetal V Patel, M.D. Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 116 S George St, York, PA 17401 Phone: 717-845-8617 Fax: 717-854-6645 | |
Dr. Stephen J Dietrich, D.O. Preventive Medicine Medicare: Medicare Enrolled Practice Location: 2250 E Market St, York, PA 17402 Phone: 717-851-1600 Fax: 717-851-1650 |